General
Preferred name
PYRIMETHAMINE
Synonyms
CPD000058714 ()
Pirimetamin ()
RP 4753 ()
Pirimecidan ()
Fansimef-pyrimethamine ()
Daraprim ()
TCMDC-125860 ()
NSC-3061 ()
TCMDC-123831 ()
Malacide ()
Chloridine ()
GNF-Pf-5586 ()
Chloridin ()
RP-4753 ()
Pyrimethaminum ()
WR-2978 ()
Pyrimethamine? ()
P&D ID
PD001771
CAS
58-14-0
19085-09-7
Tags
natural product
drug
available
Approved by
FDA
First approval
1953
Drug Status
investigational
approved
vet_approved
Drug indication
Antimalarial
Malaria
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Pyrimethamine is an antifolate compound with broad-spectrum antiprotozoal activity. It is used in the treatment and prevention of malaria as part of a combination therapy.

The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY. (GtoPdb)
DESCRIPTION Pyrimethamine is an anti-protozoal drug. It is one of the drugs in the WHO 20th Essential Medicines List (2017).
DESCRIPTION Pyrimethamine is an anti-protozoal drug. It is on the World Health Organization's List of Essential Medicines (link to 2015 list)
DESCRIPTION Potent inhibitor of multi-drug and toxin extrusion (MATE) transporters; also inhibits DHFR (Tocriscreen Plus)
DESCRIPTION Anticancer and immunosuppressive agent (Tocris Bioactive Compound Library)
DESCRIPTION Pyrimethamine is a medication used for protozoal infections. It could interfere with tetrahydrofolic acid synthesis from folic acid by inhibiting the enzyme dihydrofolate reductase. (BOC Sciences Bioactive Compounds)
Cell lines
182
Organisms
28
Compound Sets
36
Bioprocess diversity set
BOC Sciences Bioactive Compounds
pyrimethamine-cas-58-14-0-item-84-303946
Cayman Chemical Bioactives
16472
ChEMBL Approved Drugs
CHEMBL36
ChEMBL Drugs
CHEMBL36
Concise Guide to Pharmacology 2017/18
4800
Concise Guide to Pharmacology 2019/20
4800
Concise Guide to Pharmacology 2021/22
4800
Concise Guide to Pharmacology 2023/24
4800
Drug Repurposing Hub
DrugBank
DB00205
DrugBank Approved Drugs
DB00205
DrugCentral
2332
DrugCentral Approved Drugs
2332
DrugMAP
DM5X7VY
DrugMAP Approved Drugs
DM5X7VY
DrugMatrix
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101458
Guide to Pharmacology
4800
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL36
MedChem Express Bioactive Compound Library
HY-18062
Natural product-based probes and drugs
NCATS Inxight Approved Drugs
Z3614QOX8W
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Pyrimethamine
TargetMol Bioactive Compound Library
T0849
The Spectrum Collection
Tocris Bioactive Compound Library
3918
Tocriscreen Plus
3918
Welcome Trust Cancer Drugs
71
ZINC Tool Compounds
ZINC000000057464
External IDs
43
Properties
(calculated by RDKit )
Molecular Weight
248.08
Hydrogen Bond Acceptors
4
Hydrogen Bond Donors
2
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
2
cLogP
2.52
TPSA
77.82
Fraction CSP3
0.17
Chiral centers
0.0
Largest ring
6.0
QED
0.86
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Transporters
Pathway
DNA replication
Metabolism
Cell Cycle/Checkpoint
DNA Damage/DNA Repair
Anti-infection
Cell Cycle/DNA Damage
Target
Dihydrofolate reductase (DHFR)
DHFR
DHFR, SLC47A1
Antifolate
Parasite
Biological process
Nuclear-cytoplasmic transport
Primary Target
Multidrug Transporters
MOA
Inhibitor
Pharmacological Chaperones
Dihydrofolate Reductase (DHFR) Inhibitors
dihydrofolate reductase inhibitor
Member status
member
Indication
malaria
Biosynthetic Origin
Other (Folate)
Therapeutic Indication
Antiparasitic
Therapeutic Class
Antimicrobial
Antimalarials
Source data